Novartis dances into JPM with $250M Calypso buyout, $185M RNAi alliance

[cafead]

via Novartis danced into a big week in the biopharma calendar with a trio of deals. The Swiss drugmaker is paying $250 million to renew its interest in a cytokine, dropping $185 million on two RNAi cardiovascular disease candidates and handing over $37.5 million to partner with an AI-enabled biotech.

article source